Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why I downgraded GILD stock to Hold.

Gilead’s stock has since outperformed the market at the tune of 20% to -6.7%. Seeking Alpha Recently, Gilead reported Q4 and FY24 results, and its outlook for 2025.

After a run of court victories in a five-year patent dispute with the U.S. | After a run of court victories in a patent dispute with the U.S. government, Gilead has agreed to settle to resolve the ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.

Gilead Sciences, a pharma company that dominates the market for HIV treatments, agreed in June to settle a case in federal court for $40 million that had been brought by 2,625 people living with HIV.

Stockley Park, UK – 3 June 2024 – Kite, a Gilead Company, announced data from a pilot study in collaboration with Dana-Farber Cancer Institute, that demonstrate Yescarta ® (axicabtagene ciloleucel) is ...

The pipeline update marked a muted end to a molecule that was once central to Gilead’s cancer plans. In 2020, Gilead paid $4.9 billion to acquire Forty Seven, chiefly for magrolimab, to expand ...

Gilead Sciences Inc.’s stock dipped 0.2% in after-hours trading Thursday, after the drug company’s adjusted first-quarter profit was narrower than expected.

Gilead is headquartered in Foster City, California, with additional UK sites in central London, Cambridge and Stockley Park, Uxbridge. MiroBio was originally spun out of Oxford University in 2019 and ...

Gilead is stopping a phase 3 lung cancer TIGIT clinical trial—and walking away from another project—but reaffirming its commitment to Arcus by pumping a further $320 million into the biotech.